Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
Tonix Pharmaceuticals Holding Corp. (TNXP)
Last tonix pharmaceuticals holding corp. earnings: 3/24 05:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
tonixpharma.com
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical and biological products to address public health challenges and diseases with significant unmet needs, announced today that it recently held a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposed development of TNX-102 SL*, the Company's patented sublingual tablet formulation of cyclobenzaprine hydrochloride (CBP) for bedtime use for the treatment of agitation in Alzheimer’s disease (AAD). TNX-102 SL is currently in Phase 3 development for the treatment of posttraumatic stress disorder (PTSD). Seth Lederman, M.D., President and Chief Executive Officer of Tonix, stated, "We are excited by our positive dialogue with FDA regarding the potential clinical utility of TNX-102 SL for agitation in Alzheimer’s disease. Based on FDA’s feedback, Tonix has the data needed to
Show less
Read more
Impact Snapshot
Event Time:
TNXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNXP alerts
High impacting Tonix Pharmaceuticals Holding Corp. news events
Weekly update
A roundup of the hottest topics
TNXP
News
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Tonix Pharmaceuticals Announces Presentation at Planet MicroCap ShowcaseGlobeNewswire
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
TNXP
Sec Filings
- 4/15/24 - Form ARS
- 4/15/24 - Form DEF
- 4/5/24 - Form PRE
- TNXP's page on the SEC website